<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="hwp">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="pmc">neurology</journal-id><journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5791795</article-id><article-id pub-id-type="pmid">29305437</article-id><article-id pub-id-type="publisher-id">NEUROLOGY2017836635</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000004897</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>25</subject><subject>38</subject><subject>111</subject><subject>334</subject></subj-group><subj-group subj-group-type="heading"><subject>Views &#x00026; Reviews</subject></subj-group></article-categories><title-group><article-title>Dementia in Latin America</article-title><subtitle>Assessing the present and envisioning the future</subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>Parra</surname><given-names>Mario A.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Baez</surname><given-names>Sandra</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Journal of Alzheimer's Disease, associate editor, 2016</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Allegri</surname><given-names>Ricardo</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Novartis, Jannsen, Lundbeck, Ever neuropharma Educacional free.</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Nitrini</surname><given-names>Ricardo</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Advisory board meeting of Janssen-Cilag in 2012 Advisory meeting with Brazilian Nutricia board in 2013</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Funding for travel to Alzheimer Association International Congress. Novartis 2012 and 2013</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Editor - Dementia &#x00026; Neuropsychologia 2007-present Area-Editor (Neurology) - Clinics 2016 - presnt Editorial Board member- Alzheimer's Disease and Associated Disordes - 2004-present Editorial Board member - Journal of Alzheimer Disease 2016- present</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>Speaker in a meeting sponsored by Novartis in 2012 peaker in a meeting sponsored by Danone (Nutricia) in 2013</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical procedures or imaging studies:</title><list-item><p>I work in private clinic as clinical neurologist</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>FAPESP (Foundation for the support of research in the S?o Paulo State, Brazil) for epidemiology study on dementia in Brazil Conselho Nacional de Pesquisa (CNPq)</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Federico Foundation</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Lopera</surname><given-names>Francisco</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other activities:</title><list-item><p>I am principal investigator in a GRANT "API COLOMBIA" with funds from GENENTECH, BANNER INSTITUTE AND NIH</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>BANNER INSTITUTE GENENTECH</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>COLCIENCIAS GRANT NIH</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>UNIVERSITY OF ANTIOQUIA (ACADEMIC ENTITY)</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>FIDELITY FOUNDATION</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Slachevsky</surname><given-names>Andrea</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Associated Editor Journal of Alzheimer's Disease</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Custodio</surname><given-names>Nilton</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Lira</surname><given-names>David</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Piguet</surname><given-names>Olivier</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Frontiers in Dementia Research, Editorial Board, since 2011 Frontiers in Emotion Science, Editorial Board, since 2011 Behavioural Neurology, Editorial Board, since 2013 Brain Impairment, Editorial Board, since 2017</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>1) Australian Research Council, CE110001021, Centre of Excellence in Cognition and its Disorders, 2011-2018 2) National Health and Medical Research Council of Australia, APP1103258, Senior Research Fellowship 2016-2020</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>1) Velux Stiftung, Switzerland</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Kumfor</surname><given-names>Fiona</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>(1) Journal of Alzheimer's Disease, Associate Editor, 3 years, (2) Frontiers in Aging Neuroscience, Review Editor, 2 years</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>(1) National Health and Medical Research Council (NHMRC)- Australian Research Council Dementia Research Development Fellowship, APP1097026, Fellowship recipient, 2016-2019, (2) NHMRC Project Grant APP1121791</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Huepe</surname><given-names>David</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Cogram</surname><given-names>Patricia</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Frontiers Ageing Neuroscience, editor, 2 years</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>Granted: Lawrence Irwin GLASS, Michael John Bickerdike, Michael Frederick Snape, Cogram Patricia. Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid, USA, 072049, 72049. International Application: PCT/US2013/072049 Lawrence Irwin GLASS, Michael John Bickerdike, Michael Frederick Snape, Cogram Patricia. Neuroprotective bicyclic compounds and methods for their use in treating autism spectrum disorders and neurodevelopmental disorders. Patent number: WO 2015013397 File and sold - to Fraunhofer-Gesellschaft, Germany-: Patricia Cogram, Robert Deacon, Wolfgang Schuch. Method for Alzheimer's disease drug screening and biomarker evaluation. International Application: PCT/IB2014/063047 Patricia Cogram, Robert Deacon, Wolfgang Schuch. Method for Alzheimer's disease drug screening and biomarker evaluation. International Application: PCT/IB2014/062497.</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>Institute of Ecology and Biodiversity, Science Faculty, University of Chile, Chile</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Fragile X Foundation, USA. This entity awards do not have a number</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Bak</surname><given-names>Thomas</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Associate Editor of ALS FTD Journal (since January 2013). Member of Editorial Board of Behavioural Neurology (since 2008) and Aphasiology (since 2012). No compensations receieved</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Manes</surname><given-names>Facundo</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ibanez</surname><given-names>Agustin</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>CONICET, Principal Investigator, 2011 CONICYT/FONDECYT Regular Principal Investigator 1170010 FONCyT-PICT 2012-0412, Principal Investigator FONCyT-PICT 2012-1309, Principal Investigator FONDAP 15150012, Associated researcher INECO Foundation, Principal Investigator Inter-American Development Bank (IDB) Principal Investigator</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><aff>From the School of Life Sciences (M.A.P.), Psychology, University Heriot-Watt; Human Cognitive Neuroscience (M.A.P.), Psychology, Edinburgh University; Alzheimer's Scotland Dementia Research Centre and Scottish Dementia Clinical Research Network (M.A.P.), Edinburgh; Centre for Cognitive Ageing and Cognitive Epidemiology (M.A.P., T.B.) and Department of Psychology, School of Philosophy, Psychology and Language Sciences (P.C., T.B.), University of Edinburgh, UK; Universidad Aut&#x000f3;noma del Caribe (M.A.P., A.I.), Barranquilla, Colombia; Consejo Nacional de Investigaciones Cient&#x000ed;ficas y T&#x000e9;cnicas (CONICET) (S.B., F.M., A.I.); Institute of Translational and Cognitive Neuroscience (INCYT) (S.B., F.M., A.I.), INECO Foundation, Favaloro University, Buenos Aires, Argentina; Departamento de Psicolog&#x000ed;a (S.B.) Universidad de los Andes, Bogot&#x000e1;, Colombia; Department of Cognitive Neurology and Neuropsychology (R.A.), Instituto de Investigaciones Neurol&#x000f3;gicas &#x0201c;Ra&#x000fa;l Carrea&#x0201d; (FLENI) (R.A.), Buenos Aires, Argentina; Universidad de la Costa (CUC) (R.A.), Barranquilla, Colombia; Department of Neurology (R.N.), University of S&#x000e3;o Paulo Medical School, Brazil; Group of Neuroscience (F.L.), University of Antioquia, Medell&#x000ed;n, Colombia; Geroscience Center for Brain Health and Metabolism (A.S.); Physiopathology Department, ICBM, and East Neuroscience Department, Faculty of Medicine (A.S.), and Center for Advanced Research in Education (CIAE) (A.S.), University of Chile; Cognitive Neurology and Dementia, Neurology Department (A.S.), Hospital del Salvador; Neurology Department, Cl&#x000ed;nica Alemana (A.S.), Santiago, Chile; Research Unit, Peruvian Institute of Neurosciences (N.C., D.L.) and Unit Cognitive Impairment and Dementia Prevention (N.C., D.L.), Lima, Peru; Brain and Mind Centre &#x00026; School of Psychology (O.P., F.K.), Faculty of Science, University of Sydney; ARC Centre of Excellence in Cognition and its Disorders (O.P., F.K., F.M., A.I.), Sydney, Australia; Fraunhofer Chile (O.P., P.C.), Santiago; and Center for Social and Cognitive Neuroscience (CSCN), School of Psychology (D.H., A.I.), Universidad Adolfo Ib&#x000e1;&#x000f1;ez, Santiago, Chile.</aff></contrib-group><author-notes><corresp><bold>Correspondence</bold> Dr. Ibanez <email>aibanez@ineco.org.ar</email></corresp><fn fn-type="financial-disclosure"><p>Go to <ext-link ext-link-type="uri" xlink:href="http://n.neurology.org/lookup/doi/10.1212/WNL.0000000000004897">Neurology.org/N</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.</p></fn><fn fn-type="other"><p>The Article Processing Charge was funded by CONICYT-Fondecyt Regular 1170010.</p></fn></author-notes><pub-date pub-type="ppub"><day>30</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>1</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>. --><volume>90</volume><issue>5</issue><fpage>222</fpage><lpage>231</lpage><history><date date-type="received"><day>29</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>02</day><month>10</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="NEUROLOGY2017836635.pdf"/><abstract><p>The demographic structure of Latin American countries (LAC) is fast approaching that of developing countries, and the predicted prevalence of dementia in the former already exceeds the latter. Dementia has been declared a global challenge, yet regions around the world show differences in both the nature and magnitude of such a challenge. This article provides evidence and insights on barriers which, if overcome, would enable the harmonization of strategies to tackle the dementia challenge in LAC. First, we analyze the lack of available epidemiologic data, the need for standardizing clinical practice and improving physician training, and the existing barriers regarding resources, culture, and stigmas. We discuss how these are preventing timely care and research. Regarding specific health actions, most LAC have minimal mental health facilities and do not have specific mental health policies or budgets specific to dementia. In addition, local regulations may need to consider the regional context when developing treatment and prevention strategies. The support needed nationally and internationally to enable a smooth and timely transition of LAC to a position that integrates global strategies is highlighted. We focus on shared issues of poverty, cultural barriers, and socioeconomic vulnerability. We identify avenues for collaboration aimed to study unique populations, improve valid assessment methods, and generate opportunities for translational research, thus establishing a regional network. The issues identified here point to future specific actions aimed at tackling the dementia challenge in LAC.</p></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The call to fight dementia has gone global.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> However, the strategies, procedures, and tools to address this urgent issue have not, with important barriers persisting in Latin American countries (LAC) (see appendix e-1, S1, for a definition of LAC, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/WNL/A97">links.lww.com/WNL/A97</ext-link>). The demographic structure of LAC is fast approaching that of developing countries<sup><xref rid="R2" ref-type="bibr">2</xref></sup> and the predicted prevalence of dementia in the former already outreaches that in the latter.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> Although high variability among LAC exists, demographic transition in this region is happening fast. In addition, fertility rates and their relative decline have been uneven across LAC (appendix e-l, S3). Yet understanding of the factors relevant to dementia is currently limited,<sup><xref rid="R4" ref-type="bibr">4</xref></sup> and a high proportion of people with dementia in the region lack basic support.<sup><xref rid="R5" ref-type="bibr">5</xref></sup></p><sec id="s1"><title>The goal of this work</title><p>In this Perspective, we discuss the clinical and research priorities necessary to enable harmonization of strategies to tackle the dementia challenge in LAC. Regarding clinical priorities, we discuss the current diagnostic procedures (<xref ref-type="table" rid="T1">table 1</xref>), the need for improving physician training, and factors affecting timely diagnosis and care. We also consider specific issues regarding mental health facilities and policies. Regarding research priorities, we highlight the lack of epidemiologic data and the need for standardized diagnostic procedures. We also discuss the use of biomarkers and the context of clinical trials in LAC. Finally, we propose avenues for collaborations including dissemination forums, research with unique populations, and opportunities for a regional network for translational research. A consensus is needed to enter the global dementia scenario with an appealing proposal that focuses on the harmonization of actions across LAC in a way that captures global dementia strategies.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Diagnostic procedures followed by experts from the participating countries</p></caption><graphic xlink:href="NEUROLOGY2017836635TT1"/></table-wrap><p>The dementia challenge for LAC was recently highlighted in the World Congress of Neurology meeting held in Santiago, Chile.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> A group of experts from various LAC came together to discuss concerns regarding barriers and challenges in clinical research practice (appendix e-1, S2, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/WNL/A97">links.lww.com/WNL/A97</ext-link>). Four topics were addressed and are discussed here: (1) timely diagnosis, (2) therapeutic approaches, (3) social and health support after the diagnosis, and (4) potential avenues for collaboration toward unmet needs. It was acknowledged by consensus that such topics could trigger immediate actions (<xref ref-type="table" rid="T2">table 2</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Actions toward a unified working agenda for Latin American countries (LAC)</p></caption><graphic xlink:href="NEUROLOGY2017836635TT2"/></table-wrap></sec><sec id="s2"><title>Timely diagnosis</title><p>Recent dementia recommendations stress the importance of systematic and exhaustive clinical and cognitive investigations, as well as biomarker approaches, to support both the timely diagnosis of Alzheimer disease (AD)<sup><xref rid="R6" ref-type="bibr">6</xref></sup> and prevention initiatives.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> Whether such recommendations can be harmonized across the developed and developing world is unclear at present. Moreover, the potential benefit of timely diagnosis and the clinical utility of biomarkers has been questioned both at the societal and individual level.<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> Although the use of biomarkers as diagnostic criteria offers value in research settings, concerns about the premature use of biomarkers in clinical settings have been raised. Even if biomarkers are proven to be accurate for diagnosis, the associated patient benefit should be considered, particularly in light of the cost of proposed biomarkers and the necessary access to high-level equipment that is currently unavailable in most LAC.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> The utility of biomarkers is further questionable in low-income countries (LIC), where the priority should be timely diagnosis using affordable neuropsychological and clinical assessments, and appropriate patient care. Thus, the potential utility of biomarkers may be predominantly in high-income countries (HIC) and to a lesser degree in upper-middle-income countries (UMIC). Thus, the use of biomarkers may represent a step toward better future assessment predominantly in HIC,<sup><xref rid="R12" ref-type="bibr">12</xref></sup> while care and clinical assessment should be a priority in LIC and UMIC (see below). There is a stringent limit to the budget available for research in LIC and UMIC and the use of biomarkers would likely imply a tradeoff between quality of measurement and other desirable features of research such as geographic, socioeconomic, and racial diversity of sample participation as well as sample size, response rates, and cost, to mention a few.</p><p>Challenges for LAC relevant to this call include the current epidemiologic landscape, training of health care practitioners, procedures followed to make a diagnosis, and factors affecting timely diagnosis.</p></sec><sec id="s3"><title>Current epidemiologic landscape</title><p>From 2015 to 2050, the number of people with dementia in LAC is predicted to increase 4-fold.<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R13" ref-type="bibr">13</xref><xref ref-type="bibr" rid="R14">&#x02013;</xref><xref rid="R15" ref-type="bibr">15</xref></sup> By 2020, 89.28 million people with dementia will live in LMIC (in LAC: Bolivia, el Salvador, Guatemala, Honduras, Nicaragua, Paraguay), relative to the 42.18 million living in HIC. In addition, UMIC, such as Argentina, Brazil, Chile, Costa Rica, Cuba, Colombia, Dominican Republic, Ecuador, Mexico, Peru, Uruguay, and Venezuela, will experience the greatest dementia impact.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> As is the case globally, the expected increase in dementia in LAC is partly due to the aging population.<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> A combination of unsuitable diagnostic procedures and low awareness has prevented accurate estimates of dementia prevalence in LAC.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> The WHO reported a dementia prevalence of 5.5%&#x02013;7% with a standardized prevalence of 8.5%, although several LAC are underrepresented in these statistics,<sup><xref rid="R16" ref-type="bibr">16</xref></sup> and dementia prevalence may be underestimated.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> Most reports rely on a limited number of studies, which provide only a partial picture of the problem in LAC.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> Thus, more rigorous epidemiologic studies are required<sup><xref rid="R21" ref-type="bibr">21</xref></sup> (<xref ref-type="table" rid="T3">table 3</xref>).</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Epidemiologic studies in Latin American countries (LAC)</p></caption><graphic xlink:href="NEUROLOGY2017836635TT3"/></table-wrap><p>The Alzheimer's Disease International (ADI) report<sup><xref rid="R14" ref-type="bibr">14</xref></sup> included figures from Cuba, Dominican Republic, Jamaica, Peru, Venezuela, Mexico, Chile, and Brazil (14 publications). Ethnic minorities in the United States reported prevalence of dementia in Caribbean Hispanic Americans (12.2%) higher than in Mexican Americans, Japanese Americans, and non-Latino white populations.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> In fact, ADI reported the highest global prevalence of dementia in LAC (8.4%) after North Africa/Middle East (8.7%) in people &#x0003e;60 years.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> Variability of dementia prevalence rates across LAC, however, is large (ranging from 2% in Brazil<sup><xref rid="R23" ref-type="bibr">23</xref></sup> to 13.7% in Venezuela,<sup><xref rid="R24" ref-type="bibr">24</xref></sup> but this has also been reported in some European countries<sup><xref rid="R25" ref-type="bibr">25</xref></sup>). It has been suggested that such variability may result from differences in methodologic procedures across studies (e.g., diagnostic criteria). Nevertheless, the crude estimated prevalence of dementia in LAC in people &#x0003e;60 years (6.54%) exceeds international prevalence (5.2%),<sup><xref rid="R16" ref-type="bibr">16</xref></sup> demonstrating the challenge ahead for LAC (<xref ref-type="table" rid="T3">table 3</xref>).</p><p>In countries such as Cuba, Dominican Republic, Mexico, and Peru, dementia represents the largest contribution to disability.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> The Global Burden of Disease Study (2010) reported that dementia is also one of the key determinants of disability and mortality in older people.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> In some LAC, dementia leads to an increase in time disabled by over 200%, and the number of deaths due to dementia has increased by 526%. Moreover, higher rates of deaths among people with dementia in hospital settings are observed in some LAC<sup><xref rid="R27" ref-type="bibr">27</xref></sup>: Cuba 41.4%; Dominican Republic 29.1%; Peru (urban) 31.0%; Peru (rural) 83.3%; Mexico 31.3%. Notably, hospitalization is one of the main health care cost factors in dementia.</p></sec><sec id="s4"><title>Health care practitioners responsible for the diagnosis of dementia</title><p>The diagnosis of dementia in LAC is usually made by a neurologist, psychiatrist, or gerontologist, or on rare occasions, by a general practitioner.<sup><xref rid="R28" ref-type="bibr">28</xref></sup></p><sec id="s4-1"><title>Access to diagnosis</title><p>Health facilities in LAC are predominantly located in large cities, with a shortage of specialists in small towns and rural areas. In Mexico, only 34% of the rural dementia population receives support from the government<sup><xref rid="R16" ref-type="bibr">16</xref></sup> and dementia health care services are available to very few people.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> Moreover, in most LAC, specialized services are covered by private health insurance only. There are no primary health care programs to address diagnosis or timely and adequate referral, and no information is available about the process of referral, when dementia is suspected. At the secondary health level, memory clinics are very rare, although a few LAC provide dementia diagnosis via dedicated research facilities.</p></sec><sec id="s4-2"><title>Consensus criteria</title><p>In LAC, a limited number of private and public memory clinics located in large cities provide services that meet international consensus criteria and standards. The acceptance of international recommendations on dementia by local scientific/clinical/academic communities is increasing, but does not receive systematic support from relevant stakeholders. Such recommendations provide a framework for the harmonization of diagnostic procedures, to identify individuals transitioning to clinical AD.<sup><xref rid="R6" ref-type="bibr">6</xref></sup>
<xref ref-type="table" rid="T1">Table 1</xref> summarizes how current procedures in LAC map onto these recommendations. Note that in LAC, adoption of these recommendations is restricted to a few centers and does not represent the typical scenario. Although efforts are being made to adhere to such procedures, they are far from homogenous. Interestingly, the use of neuroimaging markers (e.g., amyloid/tau-PET and FDG-PET) appears to be more consistent across LAC than cognitive assessment procedures. Despite neuroimaging evidence heavily emphasized in current international dementia recommendations,<sup><xref rid="R6" ref-type="bibr">6</xref></sup> it is not clear how feasible these practices are in LAC (see &#x0201c;Procedures followed to make a diagnosis&#x0201d;).</p></sec><sec id="s4-3"><title>Training</title><p>There is an urgent need for training across different levels of the health care system, particularly at the primary care level. Limited training and low confidence of physicians contributes to dementia underdiagnosis/misdiagnosis.<sup><xref rid="R28" ref-type="bibr">28</xref></sup> A large proportion of physicians in LAC have not received training regarding differential diagnosis and have limited knowledge about the different forms of dementia.<sup><xref rid="R28" ref-type="bibr">28</xref></sup> Some training is offered through relevant national societies, and some training programs are available, but only for neurologists, geriatricians, and psychiatrists. The general scenario demonstrates an urgent need to incorporate education about dementia diagnosis and management from undergraduate and postgraduate programs through to continued education programs for health practitioners, researchers, and social care workers.</p></sec></sec><sec id="s5"><title>Procedures followed to make a diagnosis</title><p>Most LAC follow a basic 3-step clinical algorithm that comprises screening, diagnosis, and classification (i.e., dementia subtypes). Diagnosis is primarily based on clinical information and detailed cognitive assessments are primarily available in private institutions only (<xref ref-type="table" rid="T1">table 1</xref>). Availability of imaging and biomarkers is restricted to a few centers. For instance, in Argentina, a few institutions have incorporated AD biomarkers as part of international protocols (e.g., the Alzheimer&#x02019;s Disease Neuroimaging Initiative). Genetic screening is rare with some exceptions (i.e., Colombia and Argentina, not at a national level, but focused on a few centers). The Neuroscience Group of Antioquia has implemented a genetic interview to investigate family inheritance of neurologic diseases. This approach has been key to revealing an unprecedented geographic clustering of neurodegenerative genetic diseases in that country.</p><p>Basic recommendations and guidelines for dementia diagnosis are available in a subset of LAC only (e.g., Chile, Argentina, Mexico, and Brazil).<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup> In Chile, the Ministry of Health launched guidelines for primary care and a Chilean Society has launched guidelines for specialists. In Argentina, the first Clinical Practice Guidelines have been reported, while the Brazilian Academy of Neurology has made recommendations on diagnostic criteria, screening, neuropsychological evaluation, blood tests, and neuroimaging. However, a much broader health approach as recently launched in HIC<sup><xref rid="R16" ref-type="bibr">16</xref></sup> is required. Thus, although there is local awareness in some countries regarding the importance of harmonizing diagnostic procedures, this awareness has not reached a regional level (i.e., LAC). Moreover, multiple factors such as resources, culture, language, and stigmas affect the accurate diagnosis (<xref ref-type="table" rid="T4">table 4</xref>).</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Regional experience<sup>a</sup></p></caption><graphic xlink:href="NEUROLOGY2017836635TT4"/></table-wrap></sec><sec id="s6"><title>Therapeutic approaches</title><p>Experience running international or local clinical trials in LAC is mixed. A small amount of drug trials reported worldwide have included LAC, with differences among countries. This region offers an appealing environment for dementia research, although more regional integration is required (<xref ref-type="table" rid="T4">table 4</xref>). The regional experience lacks systematic organization and regional registries. In some cases, strong bias and negative stereotypes about medication have been observed.</p></sec><sec id="s7"><title>Local regulations</title><p>An important factor limiting participation of LAC in international clinical trials is the position of relevant ethics committees, which until recently have had strong reservations about clinical trials in developing countries, even when they are part of international initiatives. However, there are encouraging examples in the region, including a landmark prevention trial in familial AD in Columbia.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R29" ref-type="bibr">29</xref></sup> Some LAC have government regulations that pose challenges to clinical trials. For instance, in Chile, a new law on patients' rights and duties imposes several restrictions. Article 23 of the law 20584 prohibits the participation of vulnerable people in scientific research studies who are unable to provide consent. This has caused concerns among ethics committees, which have had to reject applications based on such legislation, affecting researchers as well as people with dementia. Also, most research is supported by industry, with academic trials representing a small proportion of research and involving small sample sizes (although this does not seem to be specific to LAC). The implications of this pattern for the direction of research as well as the validity and availability of results merits attention in future works. Finally, no regional guidelines for multicountry clinical trials exist. Thus, some local regulations may need to be revised to reflect global dementia strategies.</p></sec><sec id="s8"><title>Currently available treatments</title><p>Unlike many HIC (e.g., United Kingdom, France, Norway, United States, and South Korea) where governments have developed specific dementia plans or strategies, most LAC have minimal mental health facilities with no specific policies or budgets for mental health.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> Currently available treatments, research opportunities, and clinical assessment of dementia appears to depend on a country's political stability and economic capacity<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R30" ref-type="bibr">30</xref><xref ref-type="bibr" rid="R31">&#x02013;</xref><xref rid="R32" ref-type="bibr">32</xref></sup> (appendix e-1, S6, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/WNL/A97">links.lww.com/WNL/A97</ext-link>).</p><p>In Chile, as in many other LAC, care is mostly delivered by family relatives, with most of the cost of dementia accounted for by informal care.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> Availability of pharmaceuticals for dementia across LAC is variable, with the exception of Mexico, where the cost of dementia medications is much lower than in other LMIC.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> In Colombia and Peru, only private health insurance companies provide acetylcholinesterase inhibitors (AI) or glutamate modulators. In Chile, the public health system delivers pharmaceutical treatment for neuropsychiatric symptoms of dementia, but does not cover specific treatments for dementia subtypes. The Brazilian government supports treatment with AI for AD; however, respite facilities or nursing home access are not supported. In Argentina, AI, Souvenaid, and Cerebolysin are supported by the public health system. Moreover, patients with dementia have access to a national certificate of disability, which allows them access to full medical coverage. In general, memory enhancers are difficult to obtain. Moreover, nonpharmacologic treatments, as well as social and health support postdiagnosis, pose similar challenges in LAC (<xref ref-type="table" rid="T6">tables 5</xref> and <xref ref-type="table" rid="T6">6</xref>).</p><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Factors affecting timely diagnosis<sup>a</sup></p></caption><graphic xlink:href="NEUROLOGY2017836635TT5"/></table-wrap><table-wrap id="T6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Social and health support after diagnosis<sup>a</sup></p></caption><graphic xlink:href="NEUROLOGY2017836635TT6"/></table-wrap><p>Nonpharmacologic approaches may offer an attractive alternative for LAC. At the Alzheimer's Association International Conference 2016, evidence on cognitive intervention programs using information technology was presented. Such approaches have shown relevant improvements in cognitive functions, transfer across cognitive domains, and enhanced functioning in randomized controlled trials. Interestingly, these effects appear to persist to some extent for at least 5 years.<sup><xref rid="R33" ref-type="bibr">33</xref></sup> More recently, the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) study has combined comprehensive intervention with technology to enhance cognitive functions.<sup><xref rid="R34" ref-type="bibr">34</xref></sup> The use of technology has become common practice among older people from LAC. Some researchers have started to investigate whether this social trend could offer new opportunities to assess functioning in those at risk of dementia.<sup><xref rid="R35" ref-type="bibr">35</xref></sup> Nevertheless, we acknowledge that though promising, this area is in its infancy and more work will be needed before it can be introduced into clinical practice.</p></sec><sec id="s9"><title>Potential avenues for collaboration</title><p>Even at a global level, comprehensive dementia health care cannot be afforded by existing care models.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> The potential of LAC to tackle important priorities in dementia research is unanimously acknowledged by this expert panel.</p></sec><sec id="s10"><title>Promoting collaboration forums and large-scale computational capacity</title><p>One option for LAC is to establish an agenda to organize meetings in different countries, which could create opportunities for researchers to discuss local work and increase scientific debate and interactions (appendix e-1, S4, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/WNL/A97">links.lww.com/WNL/A97</ext-link>). Secondly, the development of large-scale computational capacity (e.g., Linux clusters) would offer a platform for intensive dementia research, screening programs, and big data analysis (appendix e-1, S4).</p></sec><sec id="s11"><title>Capitalizing on unique populations</title><p>LAC offer access to unique populations (genetic clusters, low literacy, multilingual, multiethnic).<sup><xref rid="R36" ref-type="bibr">36</xref></sup> This region hosts the world's largest populations of familial AD (Colombia), Huntington disease (Venezuela), and ataxia (Cuba), alongside multiple novel and rare functional genomic variants of other diseases. For instance, the Caribbean has a high late-onset dementia incidence, and genetic studies have shown large effect sizes.<sup><xref rid="R37" ref-type="bibr">37</xref></sup> These unique genetic presentations can be exploited at a regional level. Moreover, the socioeconomic status of several communities provides a natural scenario to study the role of vulnerability, resilience, and gene&#x02013;environment interactions, such as in the blue zones. Multilingualism is another important factor that can be studied. Many LAC are suitable for studying bilingualism and its influence on cognitive reserve in situ. In LAC, it is possible to find people who are illiterate, but still functioning at a relatively normal level within their community. In Mexico, Peru, Cuba, and Dominican Republic, education and literacy seems to protect against dementia onset.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> Studying these populations may help to disentangle the effects of education and other social factors. Finally, the development of robust cognitive neuroscience methods to tackle dementia research are now emerging in the region.<sup><xref rid="R38" ref-type="bibr">38</xref><xref ref-type="bibr" rid="R39">&#x02013;</xref><xref rid="R51" ref-type="bibr">51</xref></sup> However, the need for more research at a global level is necessary<sup><xref rid="R27" ref-type="bibr">27</xref></sup> and LAC should be integrated into this pathway.</p><p>The unique conditions found in LAC could inform causal inference by etiologic triangulation.<sup><xref rid="R52" ref-type="bibr">52</xref></sup> This triangulation from different approaches and measures can unveil key sources of potential bias. Combining different regional approaches (within LAC and among LAC and other regions) with studies at different levels (genetic, cognitive, neuronal, epidemiologic), which are available to researchers globally at a modest cost, will represent a novel advance in the field of dementia.</p></sec><sec id="s12"><title>Toward a regional network for translation research</title><p>Several LAC are currently working with animal models. Examples include the Neuroscience Group of Antioquia, Colombia; the Federal University of Rio de Janeiro, Brazil; the Max Planck Institute and the Institute of Cognitive and Translational Neuroscience in Argentina; the Geroscience Center for Brain Health and Metabolism; and the Fraunhofer Institute from Chile. Advances are being made by studying species such as the <italic>Octodon degus</italic>, an endemic rodent from Chile that spontaneously develops an analogue of dementia.<sup><xref rid="R53" ref-type="bibr">53</xref></sup> The use of low-cost accessible technologies such as inexpensive cognitive screening tools that are culturally unbiased<sup><xref rid="R54" ref-type="bibr">54</xref></sup> as well as additional measures such as high-density, portable, and even basic EEG<sup><xref rid="R40" ref-type="bibr">40</xref>,<xref rid="R45" ref-type="bibr">45</xref>,<xref rid="R55" ref-type="bibr">55</xref>,<xref rid="R56" ref-type="bibr">56</xref></sup> may provide affordable improved assessment solutions in the short term. Standardization of collection and measurement is necessary to take advantage of clinical developments, imaging, biomarkers, and clinical trials.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> It is time to do this at the LAC network level.</p></sec><sec sec-type="discussion" id="s13"><title>Discussion</title><p>The key aim of this article was to identify areas of priority on which LAC should focus, to join global research on dementia, and to harmonize clinical and research practices internationally. We have provided evidence indicating that such harmonization may need to be preceded by regional solutions to address the most imminent priorities (appendix e-1, S5, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/WNL/A97">links.lww.com/WNL/A97</ext-link>).</p><p>We have identified regional gaps and strategies. Core gaps include (1) limited reliable epidemiologic data, (2) lack of a LAC dementia strategy encouraging governments to set specific mental health policies and budgets, (3) lack of culturally valid assessment procedures and reliable diagnostic markers that enable comparison of dementia figures among LAC and internationally, and (4) lack of a unified LAC agenda to facilitate collaboration and rapid translation of research findings in the region (<xref ref-type="table" rid="T2">tables 2</xref> and <xref ref-type="table" rid="T3">3</xref> for details). Strategies to tackle these regional needs were also identified. These include (1) dissemination aimed at increasing outputs in scientific outlets, educational materials, and social media; (2) an integration agenda aimed at increasing opportunities for scientific debate and interactions, professional training, knowledge and resource exchanges, and shared IT infrastructure; and (3) a political agenda targeting relevant stakeholders, policy makers, government agencies, and international organizations to raise awareness of LAC challenges and support harmonization of strategies globally (<xref ref-type="table" rid="T2">table 2</xref>). Several unresolved issues will require joint efforts between LAC. Certainly, this is not a comprehensive treatment of all relevant issues. For instance, prevention and prevention research are important topics outside the scope of the article that should be assessed in future works. It is not entirely clear whether and how models of diagnosis and care from developed countries can be implemented, at least at present, in LAC. Given socioeconomic and sociocultural differences, we anticipate that critical modifications will be necessary.</p><p>For instance, all these topics presented above could trigger immediate actions:<list list-type="bullet"><list-item><p>There is a need for scientifically rigorous regional epidemiologic studies that systematically investigate prevalence, incidence, resilience, and cognitive reserve.</p></list-item><list-item><p>LAC need a national and a regional dementia strategy. Such strategy should be aimed at heads of governments and international agencies to encourage more regional collaboration.</p></list-item><list-item><p>Support will be needed from national/international organizations to enable a smooth and timely transition of LAC from their current status to a position that best captures global strategies.</p></list-item><list-item><p>More collaboration between LAC is urgently needed, including (1) promoting new regional collaboration forums; (2) capitalizing on unique populations; (3) working toward a regional network for translational research and assessment; and (4) developing LAC dementia registries to accelerate research discoveries.</p></list-item></list></p><p>We envisage that this opinion article will pave the way toward a LAC working agenda that will harness the support needed both to provide better care for people with dementia and to facilitate the translation of research developments into local solutions that meet global standards.</p></sec></body><back><sec sec-type="contributions"><title>Author contributions</title><p content-type="contributions">A.I. and M.A.P. designed the proposal. M.A.P., S.B., and A.I. wrote the first draft, discussed contributions from all coauthors, and approved the final version. M.A.P., A.I., and S.B. prepared the tables. All authors searched the literature, participated in discussing the contents of the paper, contributed to editing, and approved the final version of the article.</p></sec><sec sec-type="funding"><title>Study funding</title><p content-type="funding">The Expert Meeting was supported by Alzheimer's Society UK grants awarded to M.A.P. in collaboration with A.I. (AS-R42303, AS-SF-14-008). The Article Processing Charge was funded by CONICYT-Fondecyt Regular N&#x000b0;1170010.</p></sec><sec sec-type="disclosure"><title>Disclosure</title><p content-type="disclosure">M. Parra, S. Baez, R. Allegri, and R. Nitrini report no disclosures relevant to the manuscript. F. Lopera is supported by a grant API COLOMBIA funded by GENENTECH and Banner Institute. A. Slachevsky is supported by CONICYT/FONDAP /15150012, Conicyt/Fondecyt Regular/1140423, and Basal Funds for Centers of Excellence, Project FB 0003 from the Associative Research Program of CONICYT. N. Custodio and D. Lira report no disclosures relevant to the manuscript. O. Piguet is supported by an NHMRC Senior Research Fellowship (APP1103258); support from Alzheimer's Scotland Dementia Research and the Centre for Cognitive Ageing and Cognitive Epidemiology part of the cross-council Lifelong Health and Wellbeing Initiative (MR/K026992/1), both from the University of Edinburgh, is also acknowledged. F. Kumfor is supported by a National Health and Medical Research Council of Australia (NHMRC)&#x02013;Australian Research Council Dementia Research Development Fellowship (APP1097026). D. Huepe, P. Cogram, T. Bak, and F. Manes report no disclosures relevant to the manuscript. A. Ibanez is partially supported by grants from CONICET, CONICYT/FONDECYT Regular (1170010), FONCyT-PICT 2012-0412, FONCyT-PICT 2012-1309, FONDAP 15150012, INECO Foundation, and the Inter-American Development Bank. Go to <ext-link ext-link-type="uri" xlink:href="http://n.neurology.org/lookup/doi/10.1212/WNL.0000000000004897">Neurology.org/N</ext-link> for full disclosures.</p></sec><glossary><title>Glossary</title><def-list><def-item><term id="G1">AD</term><def><p>Alzheimer disease</p></def></def-item><def-item><term id="G2">ADI</term><def><p>Alzheimer's Disease International</p></def></def-item><def-item><term id="G3">AI</term><def><p>acetylcholinesterase inhibitors</p></def></def-item><def-item><term id="G4">HIC</term><def><p>high-income countries</p></def></def-item><def-item><term id="G5">LAC</term><def><p>Latin American countries</p></def></def-item><def-item><term id="G6">LIC</term><def><p>low-income countries</p></def></def-item><def-item><term id="G7">UMIC</term><def><p>upper-middle-income countries</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Albanese</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Duggan</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>Research priorities to reduce the global burden of dementia by 2025</article-title>. <source>Lancet Neurol</source>
<year>2016</year>;<volume>15</volume>:<fpage>1285</fpage>&#x02013;<lpage>1294</lpage>.<pub-id pub-id-type="pmid">27751558</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><article-title>A neurology revival in Latin America</article-title>. <source>Lancet Neurol</source>
<year>2015</year>;<volume>14</volume>:<fpage>1143</fpage>.<pub-id pub-id-type="pmid">26527174</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="book"><collab>Alzheimer's Disease International</collab>. <source>World Alzheimer Report: Executive Summary</source>. London: <collab>Alzheimer's Disease International;</collab><year>2009</year>.</mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manes</surname><given-names>F</given-names></name></person-group>
<article-title>The huge burden of dementia in Latin America</article-title>. <source>Lancet Neurol</source>
<year>2016</year>;<volume>15</volume>:<fpage>29</fpage>.<pub-id pub-id-type="pmid">26700903</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalaria</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Maestre</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>Arizaga</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>
<article-title>Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors</article-title>. <source>Lancet Neurol</source>
<year>2008</year>;<volume>7</volume>:<fpage>812</fpage>&#x02013;<lpage>826</lpage>.<pub-id pub-id-type="pmid">18667359</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubois</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hampel</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Feldman</surname><given-names>HH</given-names></name>, <etal>et al</etal></person-group>
<article-title>Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria</article-title>. <source>Alzheimers Dement</source>
<year>2016</year>;<volume>12</volume>:<fpage>292</fpage>&#x02013;<lpage>323</lpage>.<pub-id pub-id-type="pmid">27012484</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiman</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Langbaum</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Fleisher</surname><given-names>AS</given-names></name>, <etal>et al</etal></person-group>
<article-title>Alzheimer's prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments</article-title>. <source>J Alzheimer's Dis</source>
<year>2011</year>;<volume>26</volume>(<issue>suppl 3</issue>):<fpage>321</fpage>&#x02013;<lpage>329</lpage>.<pub-id pub-id-type="pmid">21971471</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sperling</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Karlawish</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>KA</given-names></name></person-group>
<article-title>Preclinical Alzheimer disease: the challenges ahead</article-title>. <source>Nat Rev Neurol</source>
<year>2013</year>;<volume>9</volume>:<fpage>54</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">23183885</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Lafortune</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Boustani</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Brayne</surname><given-names>C</given-names></name></person-group>
<article-title>The pros and cons of early diagnosis in dementia</article-title>. <source>Br J Gen Pract</source>
<year>2013</year>;<volume>63</volume>:<fpage>e510</fpage>&#x02013;<lpage>e512</lpage>.<pub-id pub-id-type="pmid">23834890</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brayne</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fox</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Boustani</surname><given-names>M</given-names></name></person-group>
<article-title>Dementia screening in primary care: is it time?</article-title>
<source>JAMA</source>
<year>2007</year>;<volume>298</volume>:<fpage>2409</fpage>&#x02013;<lpage>2411</lpage>.<pub-id pub-id-type="pmid">18042918</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cece</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Shifu</surname><given-names>X</given-names></name></person-group>
<article-title>Are the revised diagnostic criteria for Alzheimer's disease useful in low- and middle-income countries?</article-title>
<source>Shanghai Arch Psychiatry</source>
<year>2015</year>;<volume>27</volume>:<fpage>119</fpage>&#x02013;<lpage>123</lpage>.<pub-id pub-id-type="pmid">26120262</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scheltens</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Blennow</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Breteler</surname><given-names>MM</given-names></name>, <etal>et al</etal></person-group>
<article-title>Alzheimer's disease</article-title>. <source>Lancet</source>
<year>2016</year>;<volume>388</volume>:<fpage>505</fpage>&#x02013;<lpage>517</lpage>.<pub-id pub-id-type="pmid">26921134</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Prince</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Wimo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Guerchet</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Ali</surname><given-names>GC</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>YT</given-names></name>, <name name-style="western"><surname>Prina</surname><given-names>M</given-names></name></person-group>
<source>World Alzheimer Report 2015: The Global Impact of Dementia.</source>London: <collab>Alzheimer's Disease International;</collab><year>2015</year>.</mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="book"><collab>Alzheimer's Disease International. World Alzheimer Report 2015</collab>. <source>The Global impact of dementia: an analysis of prevalence, incidence, cost &#x00026; trends</source>. <publisher-name>World Alzheimer Report 2015</publisher-name> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.alz.co.uk/research/world-report-2015">alz.co.uk/research/world-report-2015</ext-link>. Accessed 2016.</mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prince</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bryce</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Albanese</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Wimo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ribeiro</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Ferri</surname><given-names>CP</given-names></name></person-group>
<article-title>The global prevalence of dementia: a systematic review and metaanalysis</article-title>. <source>Alzheimers Dement</source>
<year>2013</year>;<volume>9</volume>:<fpage>63</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">23305823</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="book"><collab>World Health Organization and Alzheimer's Disease International</collab>. <source>Dementia: A Public Health Priority</source>. Geneva: <publisher-name>World Health Organization</publisher-name>; <year>2012</year>.</mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Aparici</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Nakashima</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Strauss</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Howe</surname><given-names>N</given-names></name></person-group>
<source>Latin America's Aging Challenge: Demographics and Retirement Policy in Brazil, Chile, and Mexico</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>Center for Strategic and International Studies</publisher-name>; <year>2009</year>.</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sosa</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Albanese</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Stephan</surname><given-names>BC</given-names></name>, <etal>et al</etal></person-group>
<article-title>Prevalence, distribution, and impact of mild cognitive impairment in Latin America, China, and India: a 10/66 population-based study</article-title>. <source>PLoS Med</source>
<year>2012</year>;<volume>9</volume>:<fpage>e1001170</fpage>.<pub-id pub-id-type="pmid">22346736</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Llibre Rodriguez</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Ferri</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Acosta</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey</article-title>. <source>Lancet</source>
<year>2008</year>;<volume>372</volume>:<fpage>464</fpage>&#x02013;<lpage>474</lpage>.<pub-id pub-id-type="pmid">18657855</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prince</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Acosta</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ferri</surname><given-names>CP</given-names></name>, <etal>et al</etal></person-group>
<article-title>Dementia incidence and mortality in middle-income countries, and associations with indicators of cognitive reserve: a 10/66 Dementia Research Group population-based cohort study</article-title>. <source>Lancet</source>
<year>2012</year>;<volume>380</volume>:<fpage>50</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">22626851</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferri</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Prince</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Brayne</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>Global prevalence of dementia: a Delphi consensus study</article-title>. <source>Lancet</source>
<year>2005</year>;<volume>366</volume>:<fpage>2112</fpage>&#x02013;<lpage>2117</lpage>.<pub-id pub-id-type="pmid">16360788</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehta</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Yeo</surname><given-names>GW</given-names></name></person-group>
<article-title>Systematic review of dementia prevalence and incidence in US race/ethnic populations</article-title>. <source>Alzheimers Dement</source>
<year>2016</year>;<volume>13</volume>:<fpage>72</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">27599209</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramos-Cerqueira</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Torres</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Crepaldi</surname><given-names>AL</given-names></name>, <etal>et al</etal></person-group>
<article-title>Identification of dementia cases in the community: a Brazilian experience</article-title>. <source>J Am Geriatr Soc</source>
<year>2005</year>;<volume>53</volume>:<fpage>1738</fpage>&#x02013;<lpage>1742</lpage>.<pub-id pub-id-type="pmid">16181173</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maestre</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>Pino-Ramirez</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Molero</surname><given-names>AE</given-names></name>, <etal>et al</etal></person-group>
<article-title>The Maracaibo Aging Study: population and methodological issues</article-title>. <source>Neuroepidemiology</source>
<year>2002</year>;<volume>21</volume>:<fpage>194</fpage>&#x02013;<lpage>201</lpage>.<pub-id pub-id-type="pmid">12065882</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lobo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Launer</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Fratiglioni</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>
<article-title>Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts: Neurologic Diseases in the Elderly Research Group</article-title>. <source>Neurology</source>
<year>2000</year>;<volume>54</volume>:<fpage>S4</fpage>&#x02013;<lpage>S9</lpage>.<pub-id pub-id-type="pmid">10854354</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sousa</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Ferri</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Acosta</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Contribution of chronic diseases to disability in elderly people in countries with low and middle incomes: a 10/66 Dementia Research Group population-based survey</article-title>. <source>Lancet</source>
<year>2009</year>;<volume>374</volume>:<fpage>1821</fpage>&#x02013;<lpage>1830</lpage>.<pub-id pub-id-type="pmid">19944863</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Prince</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Comas-Herrera</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Knapp</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Guerchet</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Karagiannidou</surname><given-names>M</given-names></name></person-group>
<source>World Alzheimer Report 2016: Improving Healthcare for People Living With Dementia: Coverage, Quality and Costs Now and in the Future</source>. <publisher-loc>London</publisher-loc>: <publisher-name>Alzheimer's Disease International</publisher-name>; <year>2016</year>.</mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gleichgerrcht</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Flichtentrei</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Manes</surname><given-names>F</given-names></name></person-group>
<article-title>How much do physicians in Latin America know about behavioral variant frontotemporal dementia?</article-title>
<source>J Mol Neurosci</source>
<year>2011</year>;<volume>45</volume>:<fpage>609</fpage>&#x02013;<lpage>617</lpage>.<pub-id pub-id-type="pmid">21611804</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quiroz</surname><given-names>YT</given-names></name>, <name name-style="western"><surname>Lopera</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Budson</surname><given-names>AE</given-names></name></person-group>
<article-title>Charting the path for early diagnosis and prevention of Alzheimer's disease</article-title>. <source>Expert Rev Neurother</source>
<year>2011</year>;<volume>11</volume>:<fpage>1665</fpage>&#x02013;<lpage>1667</lpage>.<pub-id pub-id-type="pmid">22091590</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Gaona</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Quintero</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chavez</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Selga</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Maestre</surname><given-names>GE</given-names></name></person-group>
<article-title>Building capacity for dementia care in Latin America and the Caribbean</article-title>. <source>Dement Neuropsychol</source>
<year>2014</year>;<volume>8</volume>:<fpage>310</fpage>&#x02013;<lpage>316</lpage>.<pub-id pub-id-type="pmid">25932285</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ottersen</surname><given-names>OP</given-names></name>, <name name-style="western"><surname>Dasgupta</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Blouin</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>The political origins of health inequity: prospects for change</article-title>. <source>Lancet</source>
<year>2014</year>;<volume>383</volume>:<fpage>630</fpage>&#x02013;<lpage>667</lpage>.<pub-id pub-id-type="pmid">24524782</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savedoff</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>de Ferranti</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>V</given-names></name></person-group>
<article-title>Political and economic aspects of the transition to universal health coverage</article-title>. <source>Lancet</source>
<year>2012</year>;<volume>380</volume>:<fpage>924</fpage>&#x02013;<lpage>932</lpage>.<pub-id pub-id-type="pmid">22959389</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tennstedt</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Unverzagt</surname><given-names>FW</given-names></name></person-group>
<article-title>The ACTIVE study: study overview and major findings</article-title>. <source>J Aging Health</source>
<year>2013</year>;<volume>25</volume>:<fpage>3S</fpage>&#x02013;<lpage>20S</lpage>.<pub-id pub-id-type="pmid">24385638</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngandu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Lehtisalo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Solomon</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial</article-title>. <source>Lancet</source>
<year>2015</year>;<volume>385</volume>:<fpage>2255</fpage>&#x02013;<lpage>2263</lpage>.<pub-id pub-id-type="pmid">25771249</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munoz-Neira</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Lopez</surname><given-names>OL</given-names></name>, <name name-style="western"><surname>Riveros</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Nunez-Huasaf</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Flores</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Slachevsky</surname><given-names>A</given-names></name></person-group>
<article-title>The technology&#x02013;activities of daily living questionnaire: a version with a technology-related subscale</article-title>. <source>Dement Geriatr Cogn Disord</source>
<year>2012</year>;<volume>33</volume>:<fpage>361</fpage>&#x02013;<lpage>371</lpage>.<pub-id pub-id-type="pmid">22797087</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baez</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ibanez</surname><given-names>A</given-names></name></person-group>
<article-title>Dementia in Latin America: an emergent silent tsunami</article-title>. <source>Front Aging Neurosci</source>
<year>2016</year>;<volume>8</volume>:<fpage>253</fpage>.<pub-id pub-id-type="pmid">27840605</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reitz</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mayeux</surname><given-names>R</given-names></name></person-group>
<article-title>Genetics of Alzheimer's disease in Caribbean Hispanic and African American populations</article-title>. <source>Biol Psychiatry</source>
<year>2014</year>;<volume>75</volume>:<fpage>534</fpage>&#x02013;<lpage>541</lpage>.<pub-id pub-id-type="pmid">23890735</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sedeno</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Piguet</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Abrevaya</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Tackling variability: a multicenter study to provide a gold-standard network approach for frontotemporal dementia</article-title>. <source>Hum Brain Mapp</source>
<year>2017</year>;<volume>38</volume>:<fpage>3804</fpage>&#x02013;<lpage>3822</lpage>.<pub-id pub-id-type="pmid">28474365</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Abrevaya</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kozono</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>
<article-title>The cerebellum and embodied semantics: evidence from a case of genetic ataxia due to STUB1 mutations</article-title>. <source>J Med Genet</source>
<year>2017</year>;<volume>54</volume>:<fpage>114</fpage>&#x02013;<lpage>124</lpage>.<pub-id pub-id-type="pmid">27811304</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dottori</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sedeno</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Martorell Caro</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Towards affordable biomarkers of frontotemporal dementia: a classification study via network's information sharing</article-title>. <source>Sci Rep</source>
<year>2017</year>;<volume>7</volume>:<fpage>3822</fpage>.<pub-id pub-id-type="pmid">28630492</pub-id></mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abrevaya</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sedeno</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fitipaldi</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>The road less traveled: alternative pathways for action-verb processing in Parkinson's disease</article-title>. <source>J Alzheimer's Dis</source>
<year>2017</year>;<volume>55</volume>:<fpage>1429</fpage>&#x02013;<lpage>1435</lpage>.<pub-id pub-id-type="pmid">27834777</pub-id></mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sede&#x000f1;o</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Couto</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Garc&#x000ed;a-Cordero</surname><given-names>I</given-names></name>, <etal>et al</etal></person-group>
<article-title>Brain network organization and social executive performance in frontotemporal dementia</article-title>. <source>J Int Neuropsychol Soc</source>
<year>2016</year>;<volume>22</volume>:<fpage>250</fpage>&#x02013;<lpage>262</lpage>.<pub-id pub-id-type="pmid">26888621</pub-id></mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melloni</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Billeke</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Baez</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Your perspective and my benefit: multiple lesion models of self-other integration strategies during social bargaining</article-title>. <source>Brain</source>
<year>2016;139:3022&#x02013;3040</year>.</mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garc&#x000ed;a-Cordero</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Sede&#x000f1;o</surname><given-names>L</given-names></name>, <name name-style="western"><surname>de la Fuente</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>
<article-title>Feeling, learning from, and being aware of inner states: interoceptive dimensions in neurodegeneration and stroke</article-title>. <source>Philos Trans R Soc Lond B Bio Sci</source>
<year>2016</year>;<volume>371</volume>:<fpage>20160006</fpage>.<pub-id pub-id-type="pmid">28080965</pub-id></mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melloni</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sedeno</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Hesse</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>
<article-title>Cortical dynamics and subcortical signatures of motor-language coupling in Parkinson's disease</article-title>. <source>Sci Rep</source>
<year>2015</year>;<volume>5</volume>:<fpage>11899</fpage>.<pub-id pub-id-type="pmid">26152329</pub-id></mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibanez</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Manes</surname><given-names>F</given-names></name></person-group>
<article-title>Contextual social cognition and the behavioral variant of frontotemporal dementia</article-title>. <source>Neurology</source>
<year>2012</year>;<volume>78</volume>:<fpage>1354</fpage>&#x02013;<lpage>1362</lpage>.<pub-id pub-id-type="pmid">22529204</pub-id></mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pietto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Parra</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Trujillo</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>
<article-title>Behavioral and electrophysiological correlates of memory binding deficits in patients at different risk levels for Alzheimer's disease</article-title>. <source>J Alzheimers Dis</source>
<year>2016</year>;<volume>53</volume>:<fpage>1325</fpage>&#x02013;<lpage>1340</lpage>.<pub-id pub-id-type="pmid">27372640</pub-id></mixed-citation></ref><ref id="R48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parra</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Saarimaki</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Bastin</surname><given-names>ME</given-names></name>, <etal>et al</etal></person-group>
<article-title>Memory binding and white matter integrity in familial Alzheimer's disease</article-title>. <source>Brain</source>
<year>2015</year>;<volume>138</volume>:<fpage>1355</fpage>&#x02013;<lpage>1369</lpage>.<pub-id pub-id-type="pmid">25762465</pub-id></mixed-citation></ref><ref id="R49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parra</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Abrahams</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Logie</surname><given-names>RH</given-names></name>, <name name-style="western"><surname>Mendez</surname><given-names>LG</given-names></name>, <name name-style="western"><surname>Lopera</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Della Sala</surname><given-names>S</given-names></name></person-group>
<article-title>Visual short-term memory binding deficits in familial Alzheimer's disease</article-title>. <source>Brain</source>
<year>2010</year>;<volume>133</volume>:<fpage>2702</fpage>&#x02013;<lpage>2713</lpage>.<pub-id pub-id-type="pmid">20624814</pub-id></mixed-citation></ref><ref id="R50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Cordero</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Sedeno</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fraiman</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Stroke and neurodegeneration induce different connectivity aberrations in the insula</article-title>. <source>Stroke</source>
<year>2015</year>;<volume>46</volume>:<fpage>2673</fpage>&#x02013;<lpage>2677</lpage>.<pub-id pub-id-type="pmid">26185182</pub-id></mixed-citation></ref><ref id="R51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baez</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pino</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Berrio</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Corticostriatal signatures of schadenfreude: evidence from Huntington's disease</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2018</year>;<volume>89</volume>:<fpage>112</fpage>&#x02013;<lpage>116</lpage>.<pub-id pub-id-type="pmid">28765320</pub-id></mixed-citation></ref><ref id="R52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawlor</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Tilling</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Davey Smith</surname><given-names>G</given-names></name></person-group>
<article-title>Triangulation in aetiological epidemiology</article-title>. <source>Int J Epidemiol</source>
<year>2016</year>;<volume>45</volume>:<fpage>1866</fpage>&#x02013;<lpage>1886</lpage>.<pub-id pub-id-type="pmid">28108528</pub-id></mixed-citation></ref><ref id="R53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ardiles</surname><given-names>AO</given-names></name>, <name name-style="western"><surname>Tapia-Rojas</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Mandal</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Postsynaptic dysfunction is associated with spatial and object recognition memory loss in a natural model of Alzheimer's disease</article-title>. <source>Proc Natl Acad Sci USA</source>
<year>2012</year>;<volume>109</volume>:<fpage>13835</fpage>&#x02013;<lpage>13840</lpage>.<pub-id pub-id-type="pmid">22869717</pub-id></mixed-citation></ref><ref id="R54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parra</surname><given-names>M</given-names></name></person-group>
<article-title>Overcoming barriers in cognitive assessment of Alzheimer's disease</article-title>. <source>Dement Neuropsychol</source>
<year>2014</year>;<volume>8</volume>:<fpage>95</fpage>&#x02013;<lpage>98</lpage>.<pub-id pub-id-type="pmid">29213888</pub-id></mixed-citation></ref><ref id="R55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibanez</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Parra</surname><given-names>MA</given-names></name></person-group>
<article-title>Mapping memory binding onto the connectome's temporal dynamics: toward a combined biomarker for Alzheimer's disease</article-title>. <source>Front Hum Neurosci</source>
<year>2014</year>;<volume>8</volume>:<fpage>237</fpage>.<pub-id pub-id-type="pmid">24795601</pub-id></mixed-citation></ref><ref id="R56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scally</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Calderon</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Anghinah</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Parra</surname><given-names>M</given-names></name></person-group>
<article-title>Event-related potentials in the continuum of Alzheimer's disease: would they suit recent guidelines for preclinical assessment?</article-title>
<source>J Clin Diagn Res</source>
<year>2016</year>;<volume>4</volume>.</mixed-citation></ref></ref-list></back></article>